Engineering antibody therapeutics. (June 2016)

• Record Type: Journal Article
• Authors: Chiu, Mark L; Gilliland, Gary L
• Is Part Of: Current opinion in structural biology. Volume 38(2016)
• Page Start: 163
• Page End: 173
• Publication Date: 2016-06
• Subjects: Molecular biology -- Periodicals; 570
• DOI: 10.1016/j.sbi.2016.07.012
• Languages: English
• ISSNs: 0959-440X

Abstract

Highlights: Therapeutic Abs come from critical screenings of in vivo and in vitro methods. Bispecific Abs increase specificity and broaden the range of therapeutic MOA. Optimized Ab leads undergo HFA, affinity maturation, and developability assessment. Fc optimization is critical for antibody pharmacokinetics and pharmacodynamics. Abstract : The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional characterization of immunoglobulins has resulted in the engineering of antibodies to produce protein therapeutics with unique properties, both biological and biophysical, that are leading to novel therapeutic approaches. Antibody engineering includes the introduction of the antibody combining site (variable regions) into a host of architectures including bi and multi-specific formats that further impact the therapeutic properties leading to further advantages and successes in patient treatment.